IRIS
SANTARPIA, Mariacarmela
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 6.445
NA - Nord America 6.229
AS - Asia 3.716
SA - Sud America 1.339
Continente sconosciuto - Info sul continente non disponibili 431
AF - Africa 123
OC - Oceania 10
Totale 18.293
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.056
RU - Federazione Russa 3.417
SG - Singapore 1.484
BR - Brasile 1.140
CN - Cina 1.006
IE - Irlanda 673
SE - Svezia 538
IT - Italia 504
HK - Hong Kong 397
VN - Vietnam 297
GB - Regno Unito 268
PL - Polonia 215
DE - Germania 204
FR - Francia 173
FI - Finlandia 148
IN - India 111
UA - Ucraina 93
BD - Bangladesh 90
CA - Canada 64
AR - Argentina 61
ID - Indonesia 49
AT - Austria 48
IQ - Iraq 44
MX - Messico 44
EC - Ecuador 40
ZA - Sudafrica 37
TR - Turchia 33
ES - Italia 28
MA - Marocco 28
CO - Colombia 27
JP - Giappone 25
NL - Olanda 25
BE - Belgio 22
UZ - Uzbekistan 22
VE - Venezuela 21
AE - Emirati Arabi Uniti 16
CR - Costa Rica 15
PK - Pakistan 15
TN - Tunisia 15
CL - Cile 14
PY - Paraguay 13
KE - Kenya 12
MY - Malesia 12
CZ - Repubblica Ceca 11
PE - Perù 11
GR - Grecia 10
IL - Israele 10
JM - Giamaica 10
NP - Nepal 10
AZ - Azerbaigian 9
DO - Repubblica Dominicana 9
KZ - Kazakistan 9
SA - Arabia Saudita 9
AU - Australia 8
GT - Guatemala 8
RS - Serbia 8
TH - Thailandia 8
AL - Albania 7
BG - Bulgaria 7
EE - Estonia 7
LT - Lituania 7
PA - Panama 7
PH - Filippine 7
UY - Uruguay 7
CI - Costa d'Avorio 6
DZ - Algeria 6
EG - Egitto 6
JO - Giordania 6
KG - Kirghizistan 6
KR - Corea 6
BO - Bolivia 5
CH - Svizzera 5
NI - Nicaragua 5
OM - Oman 5
BY - Bielorussia 4
IR - Iran 4
AM - Armenia 3
LB - Libano 3
MD - Moldavia 3
SK - Slovacchia (Repubblica Slovacca) 3
TT - Trinidad e Tobago 3
XK - ???statistics.table.value.countryCode.XK??? 3
AO - Angola 2
CG - Congo 2
EU - Europa 2
GE - Georgia 2
HN - Honduras 2
HR - Croazia 2
KH - Cambogia 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
LV - Lettonia 2
MN - Mongolia 2
MT - Malta 2
NO - Norvegia 2
PS - Palestinian Territory 2
PT - Portogallo 2
RO - Romania 2
SN - Senegal 2
SY - Repubblica araba siriana 2
Totale 17.841
Salva come PNG Salva come JPEG
Città #
Moscow 1.014
Ashburn 1.008
Singapore 780
Dublin 672
Dallas 577
Chandler 422
Hong Kong 394
San Jose 352
Nyköping 306
Beijing 294
Jacksonville 232
Council Bluffs 225
Warsaw 209
Messina 184
The Dalles 180
Los Angeles 163
Lancaster 144
Princeton 132
Medford 121
Lauterbourg 107
New York 105
Dearborn 98
Cambridge 92
Des Moines 91
Ho Chi Minh City 84
São Paulo 78
Ann Arbor 77
Santa Clara 72
Munich 70
Hanoi 60
Redondo Beach 58
Rome 48
Rio de Janeiro 47
Guangzhou 46
Tianjin 45
Buffalo 43
Turku 43
Orem 39
Boardman 38
Atlanta 37
Wilmington 37
Chicago 35
Vienna 35
Dong Ket 32
Frankfurt am Main 29
Brooklyn 28
Jakarta 28
Milan 28
Shenyang 28
Jinan 27
Seattle 27
Montreal 26
San Mateo 26
Nuremberg 23
Shanghai 23
Tokyo 23
Brussels 22
Pune 22
Johannesburg 21
Quito 21
Denver 19
Houston 19
Tashkent 19
London 18
Phoenix 18
Belo Horizonte 17
Chennai 17
Columbus 17
Düsseldorf 17
Baghdad 16
Curitiba 16
San Francisco 16
Boston 15
Brasília 15
Porto Alegre 15
Catania 14
Haiphong 14
Mumbai 14
Nanjing 14
Salvador 14
San José 14
Amsterdam 12
Biên Hòa 12
Da Nang 12
Helsinki 12
Woodbridge 12
Zhengzhou 12
Bexley 11
Dhaka 11
Goiânia 11
Hebei 11
Hyderabad 11
Lappeenranta 11
Memphis 11
Poplar 11
Stockholm 11
Washington 11
Campinas 10
Guayaquil 10
Mexico City 10
Totale 9.878
Salva come PNG Salva come JPEG
Nome #
Neuropsychiatric Adverse Events with Monoclonal Antibodies Approved for Multiple Myeloma: An Analysis from the FDA Adverse Event Reporting System 257
Bone and lymph node metastases from occult mammary carcinoma: a case report of carcinoma of unknown primary (CUP) Syndrome 244
Immune checkpoint inhibitors and neurotoxicity: a focus on diagnosis and management for a multidisciplinary approach 239
Amplification and overexpression of the PSMB5 gene contributes to bortezomib resistance in retreatment of patients with multiple myeloma. 238
Safety profile of tyrosine kinase inhibitors used in non-small-cell lung cancer: An analysis from the Italian pharmacovigilance database 235
A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations 235
Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy 229
Anthracyclines and regional myocardial damage in breast cancer patients. A multicentre study from the Working Group on Drug Cardiotoxicity and Cardioprotection, Italian Society of Cardiology (SIC) 213
Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy 206
Liver dysfunction in hcv infected patients with CD20-Positive B-Cell Lymphoma undergoing rituximab combination chemotherapy 203
EML4-ALK fusion gene in lung adenocarcinoma: A retrospective analysis of the outcome of cisplatin plus pemetrexed treated patients. 202
High-dose Radiotherapy for Oligo-progressive NSCLC Receiving EGFR Tyrosine Kinase Inhibitors: Real World Data 201
Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer 194
Liquid biopsy for lung cancer early detection 194
Alectinib: A selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer 193
Applications of genomics in NSCLC 190
Endocrine toxicity of immune checkpoint inhibitors (anti-PD-1/PD-L1) in advanced cancer 183
Early assessment of chemotherapy-related cardiovascular toxicity in patients with breast cancer 179
Immunotherapeutic Advances for NSCLC 164
One-third of an archivial series of papillary thyroid cancer (Years 2007-2015) has coexistent chronic lymphocytic thyroiditis, which is associated with a more favorable Tumor-node-metastasis staging 163
Author Correction to: Prevalence of Use and Cost of Biological Drugs for Cancer Treatment: A 5-Year Picture from Southern Italy 163
Targeted drugs in small-cell lung cancer 158
ADCs and TCE in SCLC Therapy: The Beginning of a New Era? 156
Cardiotoxicity Induced by Immune Checkpoint Inhibitors: What a Cardio-Oncology Team Should Know and Do 156
Association between XPD 312 single nucleotide polymorphism (SNP) and clinical outcome in stage IIIA-B non-small-cell lung cancer (NSCLC) patients (P) < 59 years (Y) treated with chemotherapy followed by surgery 156
Activation of viral defense signaling in cancer 155
5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer 155
Amphiregulin contained in NSCLC-exosomes induces osteoclast differentiation through the activation of EGFR pathway 153
Age-related genetic abnormalities: the Achilles’ heel for customizing therapy in elderly lung cancer patients 150
Erlotinib therapy in a patient with non-small-cell lung cancer and brain metastases 149
Advances in immunotherapy for treatment of lung cancer 148
Circulating biomarkers as predictors of response to immune checkpoint inhibitors in NSCLC: Are we on the right path? 147
Retrospective analiysis of P-STAT6 expression as predictive marker in primary nervous system lymphoma patients assigned to high-dose methotrexate 143
Efficacy and toxicity of weekly Docetaxel as second/third line chemotherapy for advanced Non Small Cell lung cancer (NSCLC) 135
Liquid biopsy in non-small cell lung cancer: a comparison between different methodologies to detect somatic mutations 131
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer 130
Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC) 130
Adaptive Resistance Mechanisms in EGFR Mutant NSCLC 129
Management of Endocrine and Metabolic Toxicities of Immune-Checkpoint Inhibitors: From Clinical Studies to a Real-Life Scenario 126
Retrospective analysis of P-STAT6 expression as a predictive marker in primary nervous system lymphoma patients assigned to high-dose methotrexate 125
On the pharmacogenetics of non-small cell lung cancer treatment 125
Emerging drugs for non-small-cell lung cancer. 120
A friendly approach to pesonalized treatment in lung adenocarcinoma. REVISTA COLOMBIANA DE HEMATOLOGÍA Y ONCOLOGÍA 120
Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity 120
Comparison Study of the Safety Profile of Olaparib Versus Niraparib: Analysis of Real-World Data from EudraVigilance 119
Myeloid-derived suppressor cells absolute counts in predicting durable response to R-CHOP in patients with follicular lymphoma. 119
KRAS driven expression signature has prognostic power superior to mutation status in non-small cell lung cancer 119
DNA repair and mitotic checkpoint genes as potential predictors of chemotherapy response in non-small-cell lung cancer. 117
'Why is survival with triple negative breast cancer so low? insights and talking points from preclinical and clinical research' 116
PIK3CA mutations in breast cancer: a potential marker 115
MiRNAs and Microbiota in Non-Small Cell Lung Cancer (NSCLC): Implications in Pathogenesis and Potential Role in Predicting Response to ICI Treatment 114
How did the Introduction of Biosimilar Filgrastim Influence the Prescribing Pattern of Granulocyte Colony-Stimulating Factors? Results from a Multicentre, Population-Based Study, from Five Italian Centres in the Years 2009–2014 114
Molecular characterization of synchronous sporadic colorectal carcinomas 113
Polymorphisms in DNA repair genes modulate survival incisplatin/gemcitabine-treated non-small-cell lung cancer patients 113
Co-activation of STAT3 and YES-associated protein 1 (YAP1) pathway in EGFR-mutant NSCLC 112
A multicenter-retrospective study of non-small-cell lung carcinoma harboring uncommon epidermal growth factor receptor (EGFR) mutations: different subtypes of EGFR exon 19 deletion-insertions exhibit the clinical characteristics and prognosis of non-small cell lung carcinoma 110
Feasibility of cell-free circulating tumor DNA testing for lung cancer 110
Beyond platinum treatment for NSCLC: what does the future hold? 110
Challenges and pitfalls in the management of endocrine toxicities from immune checkpoint inhibitors: a case presentation of synchronous thyrotoxicosis and primary adrenal insufficiency in a melanoma patient 109
PIK3CA mutations and BRCA1 expression in breast cancer: potential biomarkers for chemoresistance 109
Non-small-cell lung cancer signaling pathways, metabolism, and PD-1/PD-L1 antibodies 109
Neuropsychiatric adverse drug reactions with oral tyrosine kinase inhibitors in metastatic colorectal cancer: an analysis from the FDA Adverse Event Reporting System 108
Rare histotypes of epithelial biliary tract tumors: A literature review 108
Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development-a narrative review 107
Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives 107
Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: Understanding transforming growth factor-beta role 107
Usefulness of predictive tests for cancer treatment 104
Neuropsychiatric Adverse Drug Reactions with Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors: An Analysis from the European Spontaneous Adverse Event Reporting System 103
Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. 103
History of extensive disease small cell lung cancer treatment: Time to raise the bar? a review of the literature 103
Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story? 102
Enfortumab Vedotin in metastatic bladder cancer: a case report of durable clinical efficacy in a pretreated patient 102
From the bench to the bed: individualizing treatment in non-small-cell lungcancer 102
Temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer 102
Overview on Therapeutic Options in Uncommon EGFR Mutant Non-Small Cell Lung Cancer (NSCLC): New Lights for an Unmet Medical Need 101
Radiation recall during cemiplimab therapy for locally advanced cutaneous squamous cell carcinoma 100
Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer? 100
Eribulin Mesylate for the Treatment of Metastatic Hormone-refractory and Triple-negative Breast Cancer: A Multi-institutional Real-world Report on Efficacy and Safety 100
Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints 98
Human endogenous retroviruses and cancer 96
Immunotherapy in NSCLC: A promising and revolutionary weapon 94
Targeting MET amplification in EGFR-mutant non-small-cell lung cancer 94
Therapeutic strategies for HER2-positive breast cancer with central nervous system involvement: a literature review and future perspectives 93
Polycythemia vera and essential thrombocytemia treated with IFN-ALPHA2a: Evidence of a significant clinical activity and molecular response. 93
Immune Checkpoint Inhibitors and the Kidney: A Focus on Diagnosis and Management for Personalised Medicine 92
Targeting the tumor microenvironment in triple-negative breast cancer: Biological insights and therapeutic opportunities 92
Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive 92
Melanoma: oncogenic drivers and the immune system 92
Predicting the outcome of chemotherapy for lung cancer. 91
PIK3CA mutations in breast cancer: A potential predictive marker 91
Other targeted drugs in melanoma 91
Fatal gastrointestinal toxicity with ipilimumab after BRAF/MEK inhibitor combination in a melanoma patient achieving pathological complete response 91
Personalized treatment of early-stage non-small-cell lung cancer: The challenging role of EGFR inhibitors 91
How Much Are Biosimilars Used in Clinical Practice? A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009-2013 90
Comprehensive genomic profiling of combined small cell lung cancer 90
An exploration of the clinical progression models of osimertinib in the treatment of advanced EGFR-mutant non-small cell lung cancer 89
PIK3CA mutations: a potential predictive marker in advanced breast cancer treated with antimicrotubule-based chemotherapy. 88
Genistein and Curcumin Inhibit Proliferation and Invasiveness in BRAFV600E Mutant and Wild-Type Melanoma Cells: Insights into Their Anticancer Effects 87
Safety profile of immune checkpoint inhibitors: An analysis of the Italian spontaneous reporting system database 87
Implications of XPD312 in stage IIIA-B NSCLC 86
Totale 13.237
Salva come PNG Salva come JPEG
Categoria #
all - tutte 64.764
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 64.764
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022753 0 0 32 31 22 14 39 30 8 94 188 295
2022/20231.804 153 144 65 142 100 179 47 76 837 11 39 11
2023/2024551 34 75 40 41 38 132 33 28 13 29 4 84
2024/20252.932 47 31 66 145 155 110 76 646 727 204 258 467
2025/20269.015 390 562 720 713 667 1.787 1.061 1.065 1.092 478 214 266
2026/20271.156 284 795 77 0 0 0 0 0 0 0 0 0
Totale 18.293